echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Kain Technology IPO application to register effective, will soon land on the board

    Kain Technology IPO application to register effective, will soon land on the board

    • Last Update: 2021-01-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the latest publicity of the Shanghai Stock Exchange, the listing application of Kain Technology has been registered in force recently.
    means the company is expected to be officially listed on the Board in the near future.
    prospectus, Kaying Technology's public offering is expected to raise about 1,092 million yuan, and the fund-raising plan will be mainly used for research and development of new drugs.
    Screenshot Source: Reference: 1. Kain Technology was founded in 2008, is a biotechnology-based biopharmaceutical company focused on the field of viral diseases, the company's chairman and general manager for Dr. Zhou Desheng.
    2011, Kain Technologies has introduced Junlian Capital, Haitong Kaiyuan, Seberle, Lilly Asia Fund and other strategic partners.
    according to the prospectus, There are currently a number of mature commercial varieties of Kain Technology, including recombinant human interferon alpha2b and compound glyphosate drugs, mainly used to treat viral diseases.
    the hepatitis C pan-genotype full-oral drug combination Kein solution (hydrochloric acid colopivir capsules and sophosphobwe tablets), chronic hepatitis treatment drug PYM α-2 injection, and rare disease-endetic pulmonary fibrosis treatment drug pyridoxine tablets and other varieties have recently been approved for the market.
    's official Xuanxin drug has been included in the new version of the health insurance catalog public information shows that hydrochloric acid colopave capsule is the first in 2020 by China's State Drug Administration (NMPA) "official Xuan" approved for listing of innovative drugs.
    it is a hepatitis C virus unstructic protein 5A (NS5A) inhibitor.
    NS5A is an effective target for conquering hepatitis C, there is a interferon-sensitive decision area on the NS5A protein, and NS5A regulates the replication of HCV.
    can be treated by inhibiting the NS5A protein and blocking the replication and assembly of the hepatitis C virus (HCV) virus.
    On February 12, 2020, NMPA announced the approval of Kain Technology Holdings subsidiary Kainger-led Bio-Class 1 innovative drug Colopiwe capsules to be marketed in combination with sophosphobwe to treat chronic hepatitis C virus infection in adults with primary treatment or interferon treatment, which can be combined or not combined with insanity cirrhosis of hepatitis C.
    screenshot source: NMPA's official website in the latest edition of China's national health insurance directory, Klopave is also included, the scope of application is limited to HCV genotyping test confirmed to be other than the gene 1b type of chronic hepatitis C patients.
    Technology said in a press release that Klopave is the only Chinese-made direct antiviral drug (DAA) that enters the national health insurance list.
    agreement, Kayne Technologies will give free sophosphobwe tablets from patients who purchase colopewe capsules of hydrochloric acid.
    hepatitis C combination therapy is about to be commercialized around Colopewe, Kayn Technologies has focused on developing its co-use with sophosphobwe tablets (Kein).
    According to the prospectus, the Kain program can treat the initial treatment or interferon treatment of the gene type 1, type 2, type 3, type 6 adult chronic hepatitis C virus infection, covering all major genotypes in China, can be combined or not combined compensation for cirrhosis, is China's first domestic hepatitis C pan-genotype full oral treatment program.
    , Kain Technologies has conducted three multi-center, open clinical studies on the Kain program, including 371 patients with chronic hepatitis C.
    results showed that in terms of effectiveness, the overall clinical cure rate (SVR12) was 97%, of which the SVR12 of genotype 1 subjects was 99%, the SVR12 of genotype 2 was 96%, and genotype 3 was affected. The SVR12 was 90%, the gene type 6 subject SVR12 was 98%, the combined progressive liver fibrosis or insitive cirrhosis SVR12 was 97%, and the interferon treatment SVR12 was 100%. According to the prospectus of the 3rd phase of the
    -Kain program (screenshot source: reference materials) the prospectus shows that the Kain scheme is once a day and does not contain protease inhibitors, does not require frequent detection of liver function, does not require genotyping, and is more friendly to the vast number of grass-roots patients who unconditionally carry out genotyping testing.
    this will lead to new treatment options for patients with hepatitis C.
    In addition to the above-mentioned products, Kain Technologies has 10 products under study, including chronic hepatitis B, influenza and new coronavirus diseases.
    , innovative drugs in the clinical trial phase include pyration interferon α-2 injections (hepatitis B adaptation) and KW-007 (advanced malignant tumor adaptation).
    8 other preclinical products in the study, including the treatment of chronic hepatitis B drugs KW-027, KW-034, KW-018 and KW-019, the treatment of new coronary viral disease drugs KW-041 and recombinant human interferon alpha2b, the treatment of the virus caused by the initial or relapsed skin simple herpes recombinant human interferon alpha2b spray and the treatment of influenza drugs KW-036.
    according to the prospectus, Kain Technologies will focus on research and development in the field of viral diseases such as chronic hepatitis B and influenza, and continue to develop drug combinations that improve clinical cure rates.
    , the company will also be involved in the development of new coronavirus diseases and other new infectious diseases treatment drugs.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.